General Internal Medicine

There is concern for elevation in alkaline phosphatase as a precursor for bone pathology, such as an increase in risk of bone malignancy, potentially ...

1 Answer available

Is there a maximum duration for raloxifene use?

1 Answer available

How do you approach peri-operative management of anti-resorptive therapies such as denosumab in patients undergoing joint replacement?

Does denosumab effect knee replacement or hip replacement? Should replacement occur right before or after injection?

1 Answer available

What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?

1 Answer available

Would you consider the use of an anabolic agent to promote fracture healing?

2 Answers available

Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?

2 Answers available

Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?

2 Answers available

What is your approach to managing osteoporosis in patients with end stage kidney disease?

1 Answer available

Can romosozumab be used in patients on dialysis?

1 Answer available

Is history of radiation an absolute contraindication to using parathyroid hormone (PTH) analogues?

Does it depend on location of radiation, length of radiation, and time since radiation?

3 Answers available

What is the role of kyphoplasty or vertebroplasty in patients with osteoporotic spinal fractures?

1 Answer available

In a patient with bisphosphonate induced bilateral atypical femur fractures, how would you approach timing of alternative osteoporosis treatments and surgical management?

2 Answers available

How would you approach an elderly patient with tibial plateau insufficiency fracture and normal DEXA?

Tibial plateau insufficiency fxs are not discussed in the guidelines for dx or treatment.

2 Answers available

Do you avoid PTH/PTHrP analogs in patients with recurrent/severe CPPD?

2 Answers available

Papers discussed in this category

Calcified tissue international, 2022 Oct 26

One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Genes, 2022 Oct 17

Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management.

JAMA, 2007-01-24

Risk of subsequent fracture after low-trauma fracture in men and women.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017-07

Osteoporosis in Crisis: It's Time to Focus on Fracture.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019 Dec 01

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.

JAMA network open, 2022 Oct 03

Association of Multimorbidity and Excess Mortality After Fractures Among Danish Adults.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022 Oct 17

The Economic Burden of Severe Osteoporotic Fractures in the French Healthcare Database: The FRACTOS Study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020 Mar 16

Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study.

JAMA, 1999-06-16

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005-09

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Journal of the National Cancer Institute, 2004 Dec 01

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Current medical research and opinion, 2011 Jul 25

Long-term raloxifene for postmenopausal osteoporosis.

The Journal of clinical endocrinology and metabolism, 2022 Dec 17

Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates.

J Bone Miner Res, 2024 Aug 21